vs
拜玛林制药（BMRN）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是拜玛林制药的1.6倍（$1.4B vs $874.6M），拜玛林制药净利率更高（-5.3% vs -22.3%，领先17.0%），罗布乐思同比增速更快（43.2% vs 17.0%），罗布乐思自由现金流更多（$308.6M vs $58.9M），过去两年罗布乐思的营收复合增速更高（32.9% vs 16.1%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
BMRN vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.6倍
$874.6M
营收增速更快
RBLX
高出26.2%
17.0%
净利率更高
BMRN
高出17.0%
-22.3%
自由现金流更多
RBLX
多$249.7M
$58.9M
两年增速更快
RBLX
近两年复合增速
16.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $1.4B |
| 净利润 | $-46.6M | $-316.0M |
| 毛利率 | 68.5% | 77.7% |
| 营业利润率 | -5.1% | -25.3% |
| 净利率 | -5.3% | -22.3% |
| 营收同比 | 17.0% | 43.2% |
| 净利润同比 | -137.3% | -43.9% |
| 每股收益（稀释后） | $-0.22 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRBLX
| Q4 25 | $874.6M | $1.4B | ||
| Q3 25 | $776.1M | $1.4B | ||
| Q2 25 | $825.4M | $1.1B | ||
| Q1 25 | $745.1M | $1.0B | ||
| Q4 24 | $747.3M | $988.2M | ||
| Q3 24 | $745.7M | $919.0M | ||
| Q2 24 | $712.0M | $893.5M | ||
| Q1 24 | $648.8M | $801.3M |
净利润BMRNRBLX
| Q4 25 | $-46.6M | $-316.0M | ||
| Q3 25 | $-30.7M | $-255.6M | ||
| Q2 25 | $240.5M | $-278.4M | ||
| Q1 25 | $185.7M | $-215.1M | ||
| Q4 24 | $124.9M | $-219.6M | ||
| Q3 24 | $106.1M | $-239.3M | ||
| Q2 24 | $107.2M | $-205.9M | ||
| Q1 24 | $88.7M | $-270.6M |
毛利率BMRNRBLX
| Q4 25 | 68.5% | 77.7% | ||
| Q3 25 | 82.0% | 78.2% | ||
| Q2 25 | 81.8% | 78.2% | ||
| Q1 25 | 79.7% | 78.3% | ||
| Q4 24 | 81.8% | 77.9% | ||
| Q3 24 | 74.7% | 77.7% | ||
| Q2 24 | 81.7% | 77.8% | ||
| Q1 24 | 80.7% | 77.7% |
营业利润率BMRNRBLX
| Q4 25 | -5.1% | -25.3% | ||
| Q3 25 | -6.0% | -21.8% | ||
| Q2 25 | 33.5% | -29.8% | ||
| Q1 25 | 30.0% | -24.6% | ||
| Q4 24 | 21.6% | -24.7% | ||
| Q3 24 | 15.3% | -30.4% | ||
| Q2 24 | 16.9% | -26.6% | ||
| Q1 24 | 13.6% | -37.7% |
净利率BMRNRBLX
| Q4 25 | -5.3% | -22.3% | ||
| Q3 25 | -4.0% | -18.8% | ||
| Q2 25 | 29.1% | -25.8% | ||
| Q1 25 | 24.9% | -20.8% | ||
| Q4 24 | 16.7% | -22.2% | ||
| Q3 24 | 14.2% | -26.0% | ||
| Q2 24 | 15.1% | -23.0% | ||
| Q1 24 | 13.7% | -33.8% |
每股收益（稀释后）BMRNRBLX
| Q4 25 | $-0.22 | $-0.44 | ||
| Q3 25 | $-0.16 | $-0.37 | ||
| Q2 25 | $1.23 | $-0.41 | ||
| Q1 25 | $0.95 | $-0.32 | ||
| Q4 24 | $0.65 | $-0.32 | ||
| Q3 24 | $0.55 | $-0.37 | ||
| Q2 24 | $0.55 | $-0.32 | ||
| Q1 24 | $0.46 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $6.1B | $394.5M |
| 总资产 | $7.6B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资BMRNRBLX
| Q4 25 | $1.3B | $3.1B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.0B | $2.7B | ||
| Q4 24 | $942.8M | $2.4B | ||
| Q3 24 | $675.4M | $2.3B | ||
| Q2 24 | $972.1M | $2.4B | ||
| Q1 24 | $747.0M | $2.4B |
总债务BMRNRBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BMRNRBLX
| Q4 25 | $6.1B | $394.5M | ||
| Q3 25 | $6.1B | $407.6M | ||
| Q2 25 | $6.0B | $353.2M | ||
| Q1 25 | $5.8B | $310.7M | ||
| Q4 24 | $5.7B | $221.4M | ||
| Q3 24 | $5.4B | $189.9M | ||
| Q2 24 | $5.3B | $121.5M | ||
| Q1 24 | $5.1B | $71.6M |
总资产BMRNRBLX
| Q4 25 | $7.6B | $9.6B | ||
| Q3 25 | $7.6B | $8.6B | ||
| Q2 25 | $7.5B | $7.8B | ||
| Q1 25 | $7.1B | $7.5B | ||
| Q4 24 | $7.0B | $7.2B | ||
| Q3 24 | $6.9B | $6.7B | ||
| Q2 24 | $7.1B | $6.5B | ||
| Q1 24 | $6.9B | $6.3B |
负债/权益比BMRNRBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $308.6M |
| 自由现金流率自由现金流/营收 | 6.7% | 21.8% |
| 资本支出强度资本支出/营收 | 4.7% | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | $1.4B |
8季度趋势，按日历期对齐
经营现金流BMRNRBLX
| Q4 25 | $99.6M | $607.0M | ||
| Q3 25 | $368.7M | $546.2M | ||
| Q2 25 | $185.3M | $199.3M | ||
| Q1 25 | $174.4M | $443.9M | ||
| Q4 24 | $185.6M | $184.5M | ||
| Q3 24 | $221.5M | $247.4M | ||
| Q2 24 | $118.8M | $151.4M | ||
| Q1 24 | $47.0M | $238.9M |
自由现金流BMRNRBLX
| Q4 25 | $58.9M | $308.6M | ||
| Q3 25 | $340.2M | $443.6M | ||
| Q2 25 | $168.2M | $176.7M | ||
| Q1 25 | $157.6M | $426.5M | ||
| Q4 24 | $166.1M | $120.6M | ||
| Q3 24 | $203.0M | $218.0M | ||
| Q2 24 | $97.4M | $111.7M | ||
| Q1 24 | $20.9M | $192.3M |
自由现金流率BMRNRBLX
| Q4 25 | 6.7% | 21.8% | ||
| Q3 25 | 43.8% | 32.6% | ||
| Q2 25 | 20.4% | 16.3% | ||
| Q1 25 | 21.2% | 41.2% | ||
| Q4 24 | 22.2% | 12.2% | ||
| Q3 24 | 27.2% | 23.7% | ||
| Q2 24 | 13.7% | 12.5% | ||
| Q1 24 | 3.2% | 24.0% |
资本支出强度BMRNRBLX
| Q4 25 | 4.7% | 21.1% | ||
| Q3 25 | 3.7% | 7.5% | ||
| Q2 25 | 2.1% | 2.1% | ||
| Q1 25 | 2.3% | 1.7% | ||
| Q4 24 | 2.6% | 6.5% | ||
| Q3 24 | 2.5% | 3.2% | ||
| Q2 24 | 3.0% | 4.4% | ||
| Q1 24 | 4.0% | 5.8% |
现金转化率BMRNRBLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RBLX
暂无分部数据
